 visitant ::
identificació
|
|||||||||||||||
|
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español | |||||||||
| Pàgina inicial > Articles > Articles publicats > 3-D chromatin conformation, accessibility, and gene expression profiling of triple-negative breast cancer |
(Institut d'Investigació Sanitària Illes Balears) (Institut d'Investigació Sanitària Illes Balears) (Providence Saint John's Health Center) (Institut d'Investigació Sanitària Illes Balears) (KTH Royal Institute of Technology (Suècia)) (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) (Ontario Institute for Cancer Research (Toronto Canadà))| Data: | 2023 |
| Resum: | Objectives: Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype with limited treatment options. Unlike other breast cancer subtypes, the scarcity of specific therapies and greater frequencies of distant metastases contribute to its aggressiveness. We aimed to find epigenetic changes that aid in the understanding of the dissemination process of these cancers. Data description: Using CRISPR/Cas9, our experimental approach led us to identify and disrupt an insulator element, IE8, whose activity seemed relevant for cell invasion. The experiments were performed in two well-established TNBC cellular models, the MDA-MB-231 and the MDA-MB-436. To gain insights into the underlying molecular mechanisms of TNBC invasion ability, we generated and characterized high-resolution chromatin interaction (Hi-C) and chromatin accessibility (ATAC-seq) maps in both cell models and complemented these datasets with gene expression profiling (RNA-seq) in MDA-MB-231, the cell line that showed more significant changes in chromatin accessibility. Altogether, our data provide a comprehensive resource for understanding the spatial organization of the genome in TNBC cells, which may contribute to accelerating the discovery of TNBC-specific alterations triggering advances for this devastating disease. |
| Ajuts: | Instituto de Salud Carlos III CD22/00026 Instituto de Salud Carlos III CPII22/00004 Instituto de Salud Carlos III PI22/01496 European Commission. Horizon 2020 824110 |
| Nota: | This work was supported by the Instituto de la Salud Carlos III (ISCIII) Sara Borrell project (#CD22/00026), Miguel Servet Project (#CPII22/00004), and AES 2022 (#PI22/01496) and co-funded by European Union, the Institut d'Investigació Sanitària Illes Balears (FOLIUM program and IMPETUS Call IMP21/10), the Govern de les Illes Balears (Margalida Comas program), the Fundación Francisco Cobos, the Asociación Española Contra el Cancer (AECC), the department of European Funds, University, and Culture of the Government of the Balearic Islands and the "CONTIGO Contra el Cancer de Mujer" foundation (#MERIT project). The group acknowledges support from the EASI-Genomics project, which has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 824110. This project (EPIMETN) was supported by the National Genomics Infrastructure in Stockholm, funded by Science for Life Laboratory, the Knut and Alice Wallenberg Foundation and the Swedish Research Council, and SNIC/Uppsala Multidisciplinary Center for Advanced Computational Science for assistance with massively parallel sequencing and access to the UPPMAX computational infrastructure. The funding body played no role in the design of the study and collection, analysis, interpretation of data, and in writing the manuscript. |
| Nota: | We want to acknowledge Llabata. P and NIMGenetics group for their technical support in RNA-seq. |
| Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.  |
| Llengua: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Publicat a: | BMC Genomic Data, Vol. 24 Núm. 1 (december 2023) , p. 61, ISSN 2730-6844 |
